Melatonin review finds sleep improvement signals in chronic kidney disease
Pooled trials reported better sleep scores and changes in selected blood markers, but several lipid and inflammation outcomes showed no statistically clear benefit.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Among people with chronic kidney disease, melatonin trials showed improved sleep quality scores, higher HDL cholesterol and lower malondialdehyde, an oxidative stress marker. Triglycerides, total cholesterol, LDL cholesterol and C-reactive protein did not show statistically significant changes. These findings do not establish fewer cardiovascular events or broad benefits for people without kidney disease.
Sleep and oxidative stress results varied substantially across trials. The abstract omits participant numbers, doses, durations and comparator details, limiting assessment of practical relevance.
What researchers found
Sleep quality on the PSQI scale
Melatonin versus trial comparison groups, which are not described; assessment timing is not reported. Weighted mean difference in sleep questionnaire scores.
What was tested
The researchers combined randomized trials that measured sleep, blood lipids or oxidative stress. The abstract does not identify the comparison treatments, so it cannot establish what melatonin was being tested against.
Understanding the sleep result
Sleep quality was assessed with the PSQI questionnaire. A pooled score difference describes that measured outcome; it does not show how many participants experienced a noticeable improvement or how long any improvement lasted.
The original publication
The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis.
Abuhassan Q, Ghnim ZS, Mahdi MS et al.
Front Nutr · 2026
- PubMed ID
- 41727206
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.